Odyssey Therapeutics annual free cash flow
2022
2023
2024
2025
Odyssey Therapeutics Free Cash Flow (FCF) History (ODTX)
Odyssey Therapeutics reported −$130.7M in free cash flow for fiscal 2025, a decrease of $12.5M from the previous fiscal year.
View full Odyssey Therapeutics company overviewOdyssey Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$130.7M | −$12.5M | — | — |
| 2024 | 2024-12-31 | −$118.2M | −$451,000 | — | — |
| 2023 | 2023-12-31 | −$117.8M | −$4.9M | — | −11358.15% |
| 2022 | 2022-12-31 | −$112.9M | — | — | — |
Odyssey Therapeutics quarterly free cash flow
Q4.24
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$34.7M | −$404,000 | — | — |
| Q1 2026 | 2026-03-31 | −$41.2M | −$1.6M | — | — |
| Q2 2025 | 2025-06-30 | −$34.3M | — | — | −3575.60% |
| Q1 2025 | 2025-03-31 | −$39.5M | — | — | −2061.94% |
| Q4 2024 | 2024-12-31 | −$34.6M | — | — | −1968.83% |
Odyssey Therapeutics free cash flow growth trends
Odyssey Therapeutics's latest reported quarter, Q2 2026, generated −$34.7M in free cash flow, a decrease of $404,000 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Odyssey Therapeutics source filings ↗